<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48632">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01954628</url>
  </required_header>
  <id_info>
    <org_study_id>AQX-1125-202</org_study_id>
    <nct_id>NCT01954628</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AQX-1125 in Unstable COPD</brief_title>
  <acronym>FLAGSHIP</acronym>
  <official_title>The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquinox Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquinox Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Finland: Finnish Medicines Agency</authority>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Poland: The Central Register of Clinical Trials</authority>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the effect of 12 weeks of treatment with
      once daily administration of AQX-1125 compared to placebo in subjects following
      exacerbations of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src
      Homology 2-containing Inositol-5'-Phosphatase 1) pathway.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from baseline in EXACT score</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on recurrent exacerbations as measured by EXACT (EXAcerbation of Chronic pulmonary disease Tool) in subjects with COPD following a recent exacerbation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CAT score</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the COPD Assessment Tool (CAT) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FEV1</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary objective is to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on forced expiratory volume in 1 second [FEV1]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety determined by adverse events [AEs], physical examinations, laboratory tests, electrocardiogram [ECG] and ophthalmic examinations</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary objectives are to evaluate the treatment effect of once daily administrations of AQX-1125 compared to placebo over 12 weeks on the frequency and severity of adverse events (AEs) and changes in, physical examination, vital signs, ophthalmic examination, laboratory tests, weight, electrocardiogram (ECG), and concomitant medications</description>
  </secondary_outcome>
  <other_outcome>
    <measure>AQX-1125 concentrations in plasma (trough values)</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary objectives are to evaluate the pharmacokinetics (PK) of AQX-1125 in plasma</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>AQX-1125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x AQX-1125 capsule daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 x Placebo capsule daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQX-1125</intervention_name>
    <description>Synthetic SHIP1 activator</description>
    <arm_group_label>AQX-1125</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged ≥40 years at screening

          2. History of COPD for at least 18 months prior to screening, characterised by excessive
             sputum production

          3. Chronic productive cough for at least 3 months in each of the 2 years prior to
             screening (if other causes of productive cough have been excluded) and/or an
             exacerbation of COPD with predominantly bronchitic symptoms at enrolment

          4. At least 2 documented exacerbations during the last 18 months prior to screening.

          5. Presentation of a diagnosed acute exacerbation of COPD, or have recently (within 3
             days) been discharged from hospital due to an acute exacerbation of COPD

          6. Ability to perform pulmonary function testing and with documented fixed airway
             obstruction determined by an FEV1 /FVC [forced vital capacity] ratio
             (post-bronchodilator) of &lt;0.70 and a predicted FEV1 value of 30%-80% of normal within
             the 6 months prior to Visit 1.

          7. Former smoker or current smoker, both with a smoking history of at least 10 pack
             years

        Exclusion Criteria:

          1. Diagnosis of other relevant lung disease (e.g. asthma, cystic fibrosis [CF] or
             significant non-CF bronchiectasis)

          2. Known alpha-1-antitrypsin deficiency

          3. Treatment with roflumilast or theophylline within 1 month prior to screening

          4. Lobar pneumonia, with current positive chest X-ray (CXR) or within the 3 months prior
             to screening including the presence of any new radiological infiltrate on CXR within
             the previous two weeks

          5. Hospitalisation for more than 7 days for current acute exacerbation, or the
             requirement for intubation during hospitalisation

          6. For outpatients, prior medical history indicating that previous exacerbations
             required &gt;3 weeks to stabilise
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen B Shrewsbury, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aquinox Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veena Kalia, PhD</last_name>
    <phone>604 629 9223</phone>
    <phone_ext>133</phone_ext>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen B Shrewsbury, MD</last_name>
    <phone>604 629 9223</phone>
    <phone_ext>107</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Respiratory &amp; Sleep Medicine, Westmead Hospital</name>
      <address>
        <city>Wentworthville</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>John Wheatley, MD, PhD, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Respiratory Medicine, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jørgen Vestbo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jørgen Vestbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Biomedicum Helsinki</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Lindqvist, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pekka Saarelainen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Csongrád Megyei Melkasi Betegségek Szakkórháza</name>
      <address>
        <city>Deszk</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrix Ballint, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beatrix Balint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piotr Kuna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Piotr Kuna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lung and Allergy Clinic, Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leif Bjermer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Leif Bjermer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://www.goldcopd.org/Guidelines/guidelines-resources.html</url>
    <description>GOLD COPD Guidelines</description>
  </link>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>September 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exacerbation of COPD</keyword>
  <keyword>Unstable COPD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
